Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: Generation of Reactive T Cells Based on Tumor Whole Cell Antigen Nanovaccines
A registry entry describing a trial testing a tumor whole cell antigen nanovaccine to generate reactive T cells for non-small cell lung canc…
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma [Phase 2]
Phase 2 study of LP-300 with carboplatin and pemetrexed in never-smokers with advanced lung adenocarcinoma; trial currently recruiting.
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer [Phase 2]
Phase 2 clinical trial evaluating the efficacy and safety of Anlotinib hydrochloride capsule in postoperative non-pCR patients with non-smal…
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: Electroacupuncture Combined With PD-1 Inhibitor for ECOG2 Advanced NSCLC [NA]
Ongoing clinical trial evaluating electroacupuncture combined with a PD-1 inhibitor for advanced non-small cell lung cancer in patients with…
-
CLINICAL_TRIALS trial_result · 2025-11-20Clinical Trial Update: Firmonertinib in the Treatment of EGFR(+) NSCLC Patients With Central Nervous System Metastasis
The clinical trial evaluating Firmonertinib for EGFR-positive non-small cell lung cancer patients with central nervous system metastasis has…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality [Phase 2]
A Phase 2 clinical trial evaluating TQB2102 for injection in non-small cell lung cancer with HER2 gene abnormalities is currently recruiting…
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: Expanded Access Use of Cemiplimab in Patients With Solid Tumors
Expanded access update on cemiplimab for patients with solid tumors, including non-small cell lung cancer, basal cell carcinoma, and cutaneo…
-
CLINICAL_TRIALS trial_result · 2025-11-20Clinical Trial Update: Treatment of Multifocal Lung Adenocarcinoma [NA]
This entry notes a Mayo Clinic-sponsored clinical trial for multifocal lung adenocarcinoma. The study status is TERMINATED.
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: Cognition and Patients With Lung Cancer
This ClinicalTrials.gov update describes a study evaluating cognition in patients with localized, operable non-small cell lung cancer; the t…
-
CLINICAL_TRIALS trial_result · 2025-11-19Clinical Trial Update: A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer [Phase 2]
Phase 2 trial comparing Tobemstomig plus platinum-based chemotherapy against Pembrolizumab plus platinum-based chemotherapy in previously un…
-
CLINICAL_TRIALS trial_result · 2025-11-19Clinical Trial Update: Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion [Phase 2]
Phase 2 clinical trial evaluating the efficacy and safety of furmonertinib in patients with locally advanced or metastatic non-small cell lu…
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: A Randomized Phase II Study Evaluating Upfront SRT to All Brain Metastases Followed by Ivonescimab Plus Chemotherapy Versus Upfront Ivonescimab Plus Chemotherapy in Patients With Asymptomatic Active Brain Metastases From NSCLC [Phase 2]
A randomized Phase II trial evaluates upfront stereotactic radiotherapy to all brain metastases followed by Ivonescimab plus chemotherapy ve…
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: PALACE: Cemiplimab Trial According to ctDNA Levels [Phase 2]
Phase 2 PALACE trial assesses cemiplimab guided by circulating ctDNA levels in non-small cell lung cancer and related thoracic neoplasms; th…
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC) [Phase 2]
This Phase 2 trial examines neoadjuvant atezolizumab followed by maintenance therapy for stage III non-small cell lung cancer and is current…
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: THE EFFECT OF CALISTHENIC EXERCISES ON FATIGUE AND EXERCISE ATTITUDES IN PATIENTS WITH LUNG CANCER [NA]
A clinical trial is evaluating whether calisthenic exercises can reduce fatigue and improve exercise attitudes in patients with non-small ce…
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients [Phase 2]
Phase 2 clinical trial update investigating tumor-infiltrating lymphocyte (TIL) therapy for non-small cell lung cancer. The study is current…
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation [Phase 1]
A Phase 1 study evaluating furmonertinib in NSCLC patients with EGFR exon 20 insertion mutations is ongoing; the trial is currently active b…
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC [Phase 2]
Phase 2 clinical trial evaluating ensartinib after chemoradiotherapy in patients with stage III ALK-mutated non-small cell lung cancer; the …
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment
This clinical trial update describes a study investigating circulating tumor DNA as a prognostic factor in patients with resectable Stage II…
-
CLINICAL_TRIALS trial_result · 2025-11-18Clinical Trial Update: Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr [Phase 3]
Phase 3 trial update evaluating dual immune checkpoint inhibitors in PD-L1-positive stage IV non-small cell lung cancer has completed.
-
CLINICAL_TRIALS trial_result · 2025-11-18Clinical Trial Update: Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy [Phase 2]
Phase 2 maintenance trial evaluating OSI-906 plus erlotinib versus placebo plus erlotinib in nonprogressors of platinum-based chemotherapy i…
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation [NA]
Massachusetts General Hospital describes using serial plasma NGS as a new efficacy metric to guide immunotherapy treatment discontinuation. …
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer [Phase 3]
A Phase III trial comparing SHR-8068 plus Adebrelimab and chemotherapy versus Tislelizumab plus chemotherapy for locally advanced or metasta…
-
CLINICAL_TRIALS trial_result · 2025-11-18Clinical Trial Update: Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene [Phase 2]
Phase 2 clinical trial evaluating Erlotinib in combination with OSI-906 in adults with advanced non-small cell lung cancer carrying activati…
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC [Phase 2]
This is a Phase 2 trial evaluating neoadjuvant SBRT with tislelizumab and anlotinib for resectable EGFR wild-type non-small cell lung cancer…